Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease
This SELECT prespecified analysis showed that semaglutide reduces total hospital admissions and length of stay in patients with obesity and established cardiovascular disease, demonstrating healthcare utilization benefits beyond cardiovascular event reduction.
Summary
This prespecified exploratory analysis of the SELECT randomized clinical trial determines the impact of semaglutide on total hospital admissions and duration of hospital stay.
Join us
Join the Global Primary Care Cardio Network. Membership is free.
Would you like to tell us more about yourself?
Interests
We will send you an email with a link to confirm your registration.
